Labcorp Holdings LH Covance Drug Development — impairment of floating rate note receivable
Discontinued — last reported Q1 '20
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Labcorp Holdings in its filing.
Tagged under the XBRL concept lh:Impairmentoffloatingratenotereceivable.
The official record: Labcorp Holdings’s 10-Q, filed May 8, 2020, on SEC EDGAR. View the filing →
Questions, answered.
- What does covance drug development — impairment of floating rate note receivable mean?
- A loss recorded when the value of a floating-rate loan or note held by the business is deemed uncollectible or impaired.
- How do you interpret covance drug development — impairment of floating rate note receivable?
- An increase indicates deteriorating credit quality of the borrower or adverse changes in market interest rate environments affecting the asset's value.
- How does covance drug development — impairment of floating rate note receivable compare across companies?
- Similar to credit loss provisions or asset write-downs found in the financial services or treasury operations of large healthcare conglomerates.